An independent study on European/UK growth stage Biotech remuneration

PIR International’s 2022 EU/UK Biotech Board & Executive Remuneration Study is a data-driven resource that empowers executives, investors and the boardroom with the insights they need to improve board governance, top-level business decisions and truly excel. This strictly independent, anonymised and confidential remuneration study is designed to leverage participation from the entire European and UK biotech ecosystem that will give the very latest data to drive important insights for all decision-makers in the sector.

Anticipated release Autumn 2022, PIR International’s 2022 EU/UK Biotech Board & Executive Remuneration Study will dissect Chair, Independent Non-Executive Directors and C-Suite remuneration, participation, equity level, geographic and diversity representation, in correlation to key metrics such as investment level, founder status and other quantitative and qualitative measures. All aimed to give the latest and actionable insights for company governance in the European and UK Biotech sector.